ALANINE
Molecular Excipient
| Mwt. | LogP | HBD | HBA | PSA | RB | CSP3 |
|---|---|---|---|---|---|---|
| 89.0 | -0.6 | 2 | 2 | 63.0 | 1 | 0.67 |
- CAS
- 56417
- UNII
- OF5P57N2ZX
- SYNONYMS
-
- ZINC ID(s)
- Availability
- Present in 101 ZINC catalogs
Known Active Genes
There has not been any activity reported at 10μM or less for this excipient (per ChEBML)
Clinical Trials
This compound has been an intervention in the following clincial trials (per clinicaltrials.gov).
| Code | Date | Title | Phase | Status |
|---|---|---|---|---|
| NCT00008801 | hOKT3gamma1 (Ala-Ala) for the Prevention of Human Islet Allograft Failure | Phase 1/Phase 2 | Active, Not Recruiting | |
| NCT00309439 | ALA and Prostate Cancer | Phase 2 | Active, Not Recruiting | |
| NCT02145949 | 2015-01-01 | Mechanistic Approach to Preventing Atrophy and Restoring Function in Older Adults | Phase 2 | Recruiting |
| NCT02281136 | 2014-12-01 | MUSE Study of Levulan Kerastick | Phase 2 | Not Yet Recruiting |
| NCT02209012 | 2014-08-01 | Twelve Month Follow-Up of CP0108 | Phase 3 | Recruiting |
| NCT02137785 | 2014-05-01 | Safety and Efficacy Study of Photodynamic Therapy With Levulan Kerastick + Blue Light for Actinic Keratoses on the Upper Extremities | Phase 3 | Recruiting |
| NCT02144077 | 2014-01-01 | Safety and Efficacy Study for the Treatment of Non-Aggressive Basal Cell Carcinoma With Photodynamic Therapy | Phase 3 | Recruiting |
| NCT01944059 | 2013-11-01 | Theramine® in the Prevention of Migraine Headache | Phase 4 | Active, Not Recruiting |
| NCT01893203 | 2013-08-01 | Treating Actinic Keratoses With Natural Daylight PDT: Comparing Two Light Sensitizers (ALA and MAL) | Phase 4 | Completed |
| NCT01838694 | 2013-07-01 | Double-Blinded, Randomized, Placebo-Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Biochemical Activity of Intravenous Cpn10 Administration in Subjects With Mild to Moderate SLE. | Phase 1/Phase 2 | Recruiting |
| NCT01898416 | 2013-06-01 | Safety and Efficacy Study Using 5-ALA Oral Administration as an Adjuvant Therapy on the Rate of Local Tumor Recurrence in Patients Who Have Desmoids Tumors | Phase 2 | Recruiting |
| NCT01811121 | 2013-02-01 | MEDICO-ECONOMIC EVALUATION OF SURGERY GUIDED BY FLUORESCENCE FOR THE OPTIMIZATION OF RESECTION OF GLIOBLASTOMAS | Phase 3 | Recruiting |
| NCT01522677 | 2012-01-01 | A Study of Neoadjuvant Photodynamic Immunomodulation for Colon Cancer | Phase 1/Phase 2 | Recruiting |
| NCT01478126 | 2012-01-01 | Effects of Glutamine in Ischemic Heart Disease Patients Following Cardiopulmonary Bypass | Phase 3 | Completed |
| NCT01475955 | 2011-12-01 | Short-incubation Levulan Photodynamic Therapy Versus Vehicle for Face/Scalp Actinic Keratosis (AK) | Phase 2 | Completed |
| NCT01458587 | 2011-11-01 | Levulan PDT Versus Vehicle for Extremity Actinic Keratoses (AK) | Phase 2 | Completed |
| NCT01445691 | 2011-09-01 | More Complete Removal of Malignant Brain Tumors by Fluorescence-Guided Surgery | Phase 2 | Recruiting |
| NCT01310868 | 2011-05-01 | Gliadel Wafer and Fluorescence-Guided Surgery With 5-ALA Followed by Radiation Therapy And Temozolomide in Treating Patients With Primary Glioblastoma | Phase 2 | Active, Not Recruiting |
| NCT01267253 | 2011-04-01 | Brivanib in Treating Patients With Persistent or Recurrent Cervical Cancer | Phase 2 | Suspended |
| NCT00628381 | 2011-01-01 | L-citrulline Supplementation During Sepsis | Phase 3 | Not Yet Recruiting |
| NCT01253668 | 2010-11-01 | Brivanib Metastatic Renal Cell Carcinoma | Phase 2 | Completed |
| NCT01502280 | 2010-11-01 | Fluorescence-guided Surgery for Low- and High-grade Gliomas | Phase 3 | Recruiting |
| NCT01459393 | 2010-11-01 | Comparison Between 5-aminolevulinic Acid Photodynamic Therapy Versus Cryotherapy for Actinic Keratosis Treatment | Phase 3 | Completed |
| NCT01611584 | 2010-06-01 | A Proof of Principle Study of Aminolevulinic Acid (ALA) - Induced Fluorescence Detection in Resectable Non-Small Cell Lung Cancer | Phase 1 | Withdrawn |
| NCT01051999 | 2010-02-01 | Glutamine Supplementation in Cystic Fibrosis | Phase 2 | Completed |
| NCT00888173 | 2009-07-01 | Brivanib Alaninate in Treating Patients With Recurrent or Persistent Endometrial Cancer | Phase 2 | Active, Not Recruiting |
| NCT00798252 | 2009-03-01 | Ascending Multiple-Dose Study of Brivanib Alaninate in Combination With Chemotherapeutic Agents in Subjects With Advanced Cancers | Phase 1 | Active, Not Recruiting |
| NCT01259544 | 2009-01-01 | BreathID® Test: A Non-invasive Modality to Detect Pancreatic Exocrine Insufficiency | Phase 2 | Completed |
| NCT00948324 | 2008-06-01 | Effect of Intensive Therapy Associated With CSII on β-cell Function With Newly Diagnosed Type 2 Diabetes | Phase 4 | Enrolling By Invitation |
| NCT00640471 | 2008-05-01 | Cetuximab With or Without Brivanib in Treating Patients With K-Ras Wild Type Tumours and Metastatic Colorectal Cancer | Phase 3 | Completed |
| NCT01185210 | 2007-09-01 | Investigation of Alanine in Fructose Intolerance: A Dose Ranging Study | Phase 2 | Recruiting |
| NCT00706433 | 2007-03-01 | Light Dose Ranging Study of Photodynamic Therapy (PDT) With Levulan + Blue Light Versus Vehicle + Blue Light in Severe Facial Acne | Phase 2 | Completed |
| NCT00378508 | 2006-09-01 | Anti-CD3 mAb Treatment of Recent Onset Type 1 Diabetes | Phase 2 | Active, Not Recruiting |
| NCT00239720 | 2006-03-01 | hOKT3gamma1 (Ala-Ala) for the Treatment of Psoriatic Arthritis | Phase 2 | Terminated |
| NCT00073255 | 2003-06-01 | Safety and Pharmacokinetics (PK) of hOKT3g1 (Ala-Ala) in Type 1 Diabetes Mellitus (T1DM) | Phase 1 | Completed |
| NCT00164268 | 2002-10-01 | Ke Ala Lokahi Demonstration Project for Sexual and Domestic Violence Prevention | Phase 1 | Completed |
| NCT00806572 | 2002-05-01 | Treatment With hOKT3gamma1(Ala-Ala) in T1DM | Phase 2 | Terminated |
| NCT00285194 | 2000-04-01 | hOKT3γ1 (Ala-Ala) Combined With Sirolimus and Delayed Tacrolimus in Type 1 Diabetic Islet Allograft Recipients | Phase 1/Phase 2 | Completed |
| NCT00241670 | 1999-10-01 | Fluorescence-guided Resection of Malignant Gliomas With 5-Aminolevulinic Acid | Phase 3 | Completed |
| NCT00410839 | 1999-06-01 | Studies of the Prevention of Atrial Fibrillation by ALA | Phase 2 | Active, Not Recruiting |